Elizabeth M. Swisher

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• International Trends in Concurrent Hysterectomy at Risk-Reducing Surgery in BRCA1/2 pathogenic variant carriers: A mixed-methods study

  American Journal of Obstetrics and Gynecology · 2026-06-01

• NRG-GY036: A phase III trial of one vs. two years of maintenance olaparib, with or without bevacizumab, in patients with <i>BRCA1/2</i> -mutated or homologous recombination deficient (HRD+) ovarian cancer following response to first line platinum-based chemotherapy.

  Journal of Clinical Oncology · 2026-05-28

• Genomic instability score (GIS) and real-world outcomes in patients (pts) with advanced ovarian cancer (aOC) using a U.S. health database.

  Journal of Clinical Oncology · 2026-05-28

• HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

  Clinical Cancer Research · 2026-05-27

• Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype

  Blood · 2026-05-21

• Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer

  JCO Precision Oncology · 2026-05-01

• Abstract CT044: A phase 1B investigator-initiated trial of niraparib lead-in, followed by niraparib plus dostarlimab for metastatic BRCA1/2-mutated breast, tubo-ovarian, and pancreatic cancers

  Cancer Research · 2026-04-17

• Abstract LB364: TOP1-DNA protein complex as a predictive biomarker for NKTR-102/Rucaparib combination therapy in PARP-inhibitor resistant ovarian cancer

  Cancer Research · 2026-04-17

• Abstract 2494: Prospective organoid drug profiling and clinical response correlation for patients with primary or recurrent ovarian carcinoma (OC) in the PROSPERITY study

  Cancer Research · 2026-04-03

• Abstract 2371: Outcomes after introduction of cervical cancer screening in an opioid treatment program (OTP) by offering HPV self-collect testing to an under-screened population

  Cancer Research · 2026-04-03

• Abstract 3541: Dynamics of clonal hematopoiesis in ovarian cancer survivors: Correlation with carboplatin and PARP inhibitor exposure

  Cancer Research · 2026-04-03

• Cancer genetic testing uptake in the primary care setting: Patient perspectives on barriers and facilitators throughout the testing process

  Journal of Genetic Counseling · 2026-03-26

• Patient-reported actions following receipt of pathogenic hereditary cancer genetic test results: results from a population-based screening study in primary care

  Figshare · 2026-02-18

• Additional file 1 of Patient-reported actions following receipt of pathogenic hereditary cancer genetic test results: results from a population-based screening study in primary care

  Figshare · 2026-02-18

• Patient-reported actions following receipt of pathogenic hereditary cancer genetic test results: results from a population-based screening study in primary care

  Figshare · 2026-02-18

• Additional file 1 of Patient-reported actions following receipt of pathogenic hereditary cancer genetic test results: results from a population-based screening study in primary care

  Figshare · 2026-02-18

• Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis

  JCO oncology advances. · 2026-01-01

• Cost-effectiveness of primary care-based risk assessment and hereditary cancer genetic testing

  BMC Primary Care · 2025-12-22

• Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precaution

  American Journal of Obstetrics and Gynecology · 2025-11-01

• ADAPTIVE MULTI-SCALE GRAPH TRANSFORMER FRAMEWORK FOR HISTOPATHOLOGICAL IMAGESPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-10-31